Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants

Pharmacotherapy

Volumn 26, Issue 12 I, 2006, Pages 1730-1744

  Saad, Aline H ^a,b   DePestel, Daryl D ^a,b   Carver, Peggy L ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Azole antifungals; Cyclosporine; Drug interactions; Fluconazole; Immunosuppressants; Itraconazole; Ketoconazole; Sirolimus; Tacrolimus; Voriconazole

Indexed keywords

ANTIFUNGAL AGENT; CLOTRIMAZOLE; CYCLOSPORIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; EVEROLIMUS; FLUCONAZOLE; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; KETOCONAZOLE; POSACONAZOLE; RAPAMYCIN; STEROL 14ALPHA DEMETHYLASE; TACROLIMUS; VORICONAZOLE;

AREA UNDER THE CURVE; CLINICAL PRACTICE; COST CONTROL; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REDUCTION; DRUG FORMULATION; DRUG METABOLISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC POLYMORPHISM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL DECISION MAKING; MONEY; MONOTHERAPY; MYCOSIS; NEPHROTOXICITY; REVIEW; RISK FACTOR;

ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; AZOLES; BIOLOGICAL TRANSPORT, ACTIVE; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INDUCTION; ENZYME REPRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; ORGAN TRANSPLANTATION; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC;

EID: 33845365814     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.12.1730     Document Type: Review

References (80)

1. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001;33:641-7.
2. Kontoyiannis DP, Mantadakis E, Samonis G. Systemic mycoses in the immunocompromised host: an update in antifungal therapy. J Hosp Infect 2003;53:243-58.
3. Rubin RH. Overview: pathogenesis of fungal infections in the organ transplant recipient. Transpl Infect Dis 2002;4(suppl 3):12-17.
4. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001;32(3):358-66.
5. Fung JJ. Fungal infection in liver transplantation. Transpl Infect Dis 2002;4(suppl 3):18-23.
6. Fishman JA. Overview: fungal infections in the transplant patient. Transpl Infect Dis 2002;4(suppl 3):3-11.
7. Singh N. Treatment of opportunistic mycoses: how long is long enough? Lancet Infect Dis 2003;3:703-8.
8. Rubin RH, Ikonen T, Gummert JF, Morris RE. The therapeutic prescription for the organ transplant recipient: the linkage of immunosuppression and antimicrobial strategies. Transpl Infect Dis 1999;1:29-39.
9. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf 1998;18:83-97.
10. Bates DW, Yu DT. Clinical impact of drug-drug interactions with systemic azole antifungals. Drugs Today (Barc) 2003;39:801-13.
11. Katz HI. Drug interactions of the newer oral antifungal agents. Br J Dermatol 1999;141(suppl 56):26-32.
12. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000;38:111-80.
13. Gillum JG, Israel DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 1993;25:450-82.
14. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol 2001;41:1149-79.
15. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001;40:159-68.
16. Davidson MH. Does differing metabolism by cytochrome P450 have clinical importance? Curr Atheroscler Rep 2000;2:14-19.
17. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57.
18. Hall SD, Thummel KE, Watkins PB, et al. Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 1999;27:161-6.
19. Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998;35:361-90.
20. Apseloff G, Hilligoss DM, Gardner MJ, et al. Induction of fluconazole metabolism by rifampin: in vivo study in humans. J Clin Pharmacol 1991;31:358-61.
21. Tucker WS Jr, Snell BB, Island DP, Gregg CR. Reversible adrenal insufficiency induced by ketoconazole. JAMA 1985;253:2413-14.
22. Christians U, Strom T, Zhang YL, et al. Active drug transport of immunosuppressants: new insights for pharmacokinetics and pharmacodynamics. Ther Drug Monit 2006;28(1):39-44.
23. Venkataramanan R, Zang S, Gayowski T, Singh N. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes. Antimicrob Agents Chemother 2002;46:3091-3.
24. Sansone A, Belle D, Statkevich P, et al. Effect of posaconazole on the pharmacokinetics of tacrolimus in healthy volunteers [abstr]. In: Abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 14-17, 2003. Washington, DC: American Society for Microbiology, 2003:1603.
25. Courtney RD, Statkevich P, Laughlin M, et al. Effect of posaconazole on the pharmacokinetics of cyclosporine [abstr]. In: Abstracts of the 41st interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, December 16-19, 2001. Washington, DC: American Society for Microbiology, 2001:A27.
26. Lo A, Burckart GJ. P-glycoprotein and drug therapy in organ transplantation. J Clin Pharmacol 1999;39:995-1005.
27. Benet LZ, Cummins CL, Wu CY. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 2003;4:393-8.
28. Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002;41:813-51.
29. Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother 2002;46:160-5.
30. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-58.
31. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998;38:389-430.
32. McConn DJ ll, Lin YS, Allen K, Kunze KL, Thummel KE. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. Drug Metab Dispos 2004;32:1083-91.
33. i values and impact of CYP3A5 expression. Drug Metab Dispos 1999;27:180-7.
34. Bachmann KA, Lewis JD. Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants. Ann Pharmacother 2005;39:1064-72.
35. Neal JM, Kunze KL, Levy RH, O'Reilly RA, Trager WF. Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition. Drug Metab Dispos 2003;31:1043-8.
36. Maertens JA. History of the development of azole derivatives. Clin Microbiol Infect 2004;10(suppl 1):1-10.
37. Halloran PF, Gourishankar S. Principles and overview of immunosuppression. In: Norman DJ, Turka LA, eds. Primer on transplantation, 2nd ed. Mt. Laurel, NJ: American Society of Transplantation, 2001:87-97.
38. Isoherranen N, Kunze KL, Allen KE, Nelson WL, Thummel KE. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 2004;32:1121-31.
39. Gubbins PO, Amsden JR. Drug-drug interactions of antifungal agents and implications for patient care. Expert Opin Pharmacother 2005;6:2231-43.
40. Pfizer Inc. Vfend (voriconazole) package insert. New York, NY; 2003.
41. Pearson MM, Rogers PD, Cleary JD, Chapman SW. Voriconazole: a new triazole antifungal agent. Ann Pharmacother 2003;37:420-32.
42. Ghosal A, Hapangama N, Yuan Y, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos 2004;32:267-71.
43. Slain D, Rogers PD, Cleary JD, Chapman SW. Intravenous itraconazole. Ann Pharmacother 2001;35:720-9.
44. Omar G, Whiting PH, Hawksworth GM, Humphrey MJ, Burke MD. Ketoconazole and fluconazole inhibition of the metabolism of cyclosporin A by human liver in vitro. Ther Drug Monit 1997;19:436-45.
45. Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004;21:645-53.
46. Gaston RS. Maintenance immunosuppression in the renal transplant recipient: an overview. Am J Kidney Dis 2001;38:S25-35.
47. Mahalati K, Kahan BD. Clinical pharmacokinetics of sirollmus. Clin Pharmacokinet 2001;40:573-85.
48. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral) 1 in organ transplantation. Drugs 2001;61:1957-2016.
49. Abraham MA, Thomas PP, John GT, Job V, Shankar V, Jacob CK. Efficacy and safety of low-dose ketoconazole (50 mg) to reduce the cost of cyclosporine in renal allograft recipients. Transplant Proc 2003;35:215-16.
50. Lomaestro BM, Piatek MA. Update on drug interactions with azole antifungal agents. Ann Pharmacother 1998;32:915-28.
51. Canafax DM, Graves NM, Hilligoss DM, Carleton BC, Gardner MJ, Matas AJ. Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 1991;51(5):1014-18.
52. Romero AJ, Pogamp PL, Nilsson LG, Wood N. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002;71:226-34.
53. Moreno M, Latorre A, Manzanares C, et al. Clinical management of tacrolimus drug interactions in renal transplant patients. Transplant Proc 1999;31:2252-3.
54. Toda F, Tanabe K, Ito S, et al. Tacrolimus trough level adjustment after administration of fluconazole to kidney recipients. Transplant Proc 2002;34:1733-5.
55. Hairhara Y, Makuuchi M, Kawarasaki H, et al. Effect of fluconazole on blood levels of tacrolimus [abstr]. Transplant Proc 1999;31:2767.
56. Capone D, Gentile A, Imperatore P, Palmiero G, Basile V. Effects of itraconazole on tacrolimus blood concentrations in a renal transplant recipient. Ann Pharmacother 1999;33:1124-5.
57. Billaud EM, Guillemain R, Tacco F, Chevalier P. Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients. Br J Clin Pharmacol 1998;46:271-2.
58. Banerjee R, Leaver N, Lyster H, Banner NR. Coadministration of itraconazole and tacrolimus after thoracic organ transplantation. Transplant Proc 2001;33:1600-2.
59. Wood N, Tan KKC, Allan R, Fielding A, Nichols DJ. Effect of voriconazole on the pharmacokinetics of tacrolimus [abstr]. In: Abstracts of the 41st interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, December 16-19, 2001. Washington, DC: American Society for Microbiology, 2001:A20.
60. Zimmeran JJ, Gurr JA, DiLea C. Study of the potential pharmacokinetic interaction between sirolimus (Rapamune) and ketoconazole: final report (protocol 0468E1-136-US), vol 163/2. Wyeth-Ayerst GMR-31057, 1998.
61. Thomas PP, Manivannan J, John GT, Jacob CK. Sirolimus and ketoconazole co-prescription in renal transplant recipients. Transplantation 2004;77:474-5.
62. Cervelli MJ. Fluconazole-sirolimus drug interaction. Transplantation 2002;74:1477-8.
63. Marty FM, Lowry CM, Cutler CS, et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006;12(5):552-9.
64. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995;58:15-19.
65. Osowski CL, Dix SP, Lin LS, Mullins RE, Geller RB, Wingard JR. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation 1996;61:1268-72.
66. Floren LC, Bekersky I, Benet LZ, et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997;62:41-9.
67. Manez R, Martin M, Raman V, et al. Fluconazole therapy in transplant recipients receiving FK 506. Transplantation 1994;57:1521-3.
68. Tuteja S, Alloway RR, Johnson JA, Gaber AO. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation 2001;71:1303-7.
69. Taro Pharmaceuticals. Ketoconazole package insert. Hawthorne, NY; 1999.
70. Pfizer Roerlg. Diflucan (fluconazole) package insert. New York, NY; 2004.
71. Janssen Pharmaceutica Products. Sporanox (itraconazole) package insert. Titusville, NJ; 2002.
72. Fitzsimmons WE, Bekersky I, Dressler D, Raye K, Hodosh E, Mekki Q. Demographic considerations in tacrolimus pharmacokinetics. Transplant Proc 1998;30:1359-64.
73. First MR, Schroeder TJ, Daoud J, et al. Ketoconazole is not associated with increased inpatient or outpatient resources while decreasing cyclosporine annual costs by approximately $3,300 per patient. Presented at the 16th annual meeting of the American Society of Transplant Physicians, Dallas, TX, May 11-14, 1997.
74. Martin JE, Daoud AJ, Schroeder TJ, First MR. The clinical and economic potential of cyclosporln drug interactions. Pharmacoeconomics 1999;15:317-37.
75. El-Agroudy AE, Sobh MA, Hamdy AF, Ghoneim MA. A prospective, randomized study of coadministration of ketoconazole and cyclosporine in kidney transplant recipients: ten-year follow-up. Transplantation 2004;77:1371-6.
76. Domlnguez J, Kompatzki A, Foradori A, Norambuena R. Ketoconazole alters cyclosporine pharmacokinetic profile and may predispose to acute rejection. Transplant Proc 2003;35:2522-3.
77. Rossi SJ, Martin JE, Gelhot A, et al. A randomized prospective trial of fluconazole vs. clotrimazole for fungal prophylaxis in liver transplant recipients. Presented at the 14th annual meeting of the American Society of Transplant Physicians, Chicago, IL, May 14-15, 1995.
78. El-Dahshan KF, Bakr MA, Donia AF, Badr Ael-S, Sobh MA. Co-administration of ketoconazole to tacrolimus-treated kidney transplant recipients: a prospective randomized study. Nephrol Dial Transplant 2004;19:1613-17.
79. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004;43:83-95.
80. Kovarik JM, Beyer D, Bizot MN, Jiang Q, Shenouda M, Schmouder RL. Blood concentrations of everolimus are markedly increased by ketoconazole. J Clin Pharmacol 2005;45:514-18.